NCT07062978 A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia® Status RECRUITING Phase PHASE3
NCT06804590 A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With Osteoporosis Status RECRUITING Phase PHASE3
NCT06588153 A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China Status RECRUITING Phase PHASE4
NCT06504966 Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia® Status WITHDRAWN Phase PHASE3
NCT05352516 A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture Status COMPLETED Phase PHASE3
NCT05345691 Comparison of Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With Osteoporosis Status COMPLETED Phase PHASE3
NCT05323708 Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Bmab 1000 and Prolia® in Normal Healthy Volunteers: DENARIUS: DENosumab Pharmacokinetic equivAlence tRIal in Healthy volUnteerS Status COMPLETED Phase PHASE1
NCT05087030 Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis Status COMPLETED Phase PHASE3
NCT04798313 Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW031 and Prolia® in Healthy Adults Status COMPLETED Phase PHASE1
NCT04591275 Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia® . Status COMPLETED Phase PHASE3
NCT04213105 Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Prolia® in Healthy Adults Status UNKNOWN Phase PHASE1
NCT03925051 Phase 1 Study to Compare CMAB807 Injection to Prolia® in Healthy Volunteers Status COMPLETED Phase PHASE1